EGFR and non-small cell lung carcinoma: However, some oncogenic drivers, such as sensitizing epidermal growth factor receptor (EGFR) mutation and anaplastic lymphoma kinase (ALK) rearrangements, have shown less benefit from immunotherapy for advanced NSCLC.